Key clinical point: Resuming anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) therapy was beneficial in patients with migraine who had responded to this treatment previously but relapsed upon discontinuation.
Major finding: The median monthly headache days (MHD) improved from 16 in the month before antibody reintroductio n to 8 after 3 months of treatment re-introduction. The majority of patients achieved 30% reduction in MHD (75.3%) and monthly migraine days (80.8%) during the second treatment period with anti-CGRP mAb.
Study details: This observational prospective analytical multicentric study included 360 patients with migraine who had shown prior response to anti-CGRP mAb, with clinical worsening after withdrawal and were re-introduced anti-CGRP mAb therapy.
Disclosures: This study was funded by the Instituto de Salud Carlos III, European Union, and Fondo Europeo de Desarrollo Regional (FEDER) funds. Several authors declared receiving speaker honoraria, payments or honoraria for lectures, or research support or grants from various sources.
Source: Romero Del Rincón C, Gonzalez-Martinez A, Quintas S et al. RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine. Eur J Neurol. 2024 (Jan 25). doi: 10.1111/ene.16203 Source